Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

289.50 +1.62 (+0.56%)
Streaming Delayed Price Updated: 12:45 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,077,985
Open 288.18
Bid (Size) 289.37 (2)
Ask (Size) 289.62 (9)
Prev. Close 287.87
Today's Range 284.14 - 289.83
52wk Range 260.52 - 346.85
Shares Outstanding N/A
Dividend Yield 2.94%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Decoding Amgen's Options Activity: What's the Big Picture?
Via Benzinga
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges. 
Via Benzinga

Performance

YTD
-2.65%
-2.65%
1 Month
-8.60%
-8.60%
3 Month
-12.05%
-12.05%
6 Month
-6.44%
-6.44%
1 Year
+10.15%
+10.15%

More News

Read More
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Dow Tumbles Over 300 Points Following Economic Reports, Nvidia, Microsoft Decline: Fear & Greed Index Moves To 'Neutral' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious
Via The Motley Fool
Amgen's Options Frenzy: What You Need to Know
Via Benzinga
What Analysts Are Saying About Amgen Stock
Via Benzinga
3 Healthcare Stocks For Long-Term Growth And Dividends
Via Talk Markets
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever
Via The Motley Fool
2 Dividend Stocks to Buy Hand Over Fist in November
Via The Motley Fool
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Amgen Rebounds, Shaking Off 'Overdone' Fears Tied To Its Weight-Loss Shot
Via Investor's Business Daily
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
Via Benzinga
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Don’t Confuse Brains With A Bull Market, Or Price With Value
Via Talk Markets
Investors Like Certainty. Trump's Win Gave Them Some.
Via The Motley Fool
Topics Government
Exposures Political
AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis
Via Benzinga
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
Via Investor's Business Daily
Amgen (AMGN) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.